All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Extracellular vesicles (EVs) are released by cells and found in most biological fluids including urine, plasma, cerebrospinal fluid, saliva etc. as well as in tissue culture conditioned media. EVs are thought to mediate cell-cell communication \[[@pone.0220007.ref001]\] and may carry a variety of proteins, lipids and RNA with potential to impact target cell physiology. It has been proposed that EVs modulate tumor environments to allow for tumor seeding and growth and promote angiogenesis \[[@pone.0220007.ref002]--[@pone.0220007.ref008]\]. EVs have also been implicated in the prion-like spread of neuropathogenic protein aggregates in several neurodegenerative diseases \[[@pone.0220007.ref009]--[@pone.0220007.ref015]\]. Certain viruses and bacteria such as hepatitis A virus \[[@pone.0220007.ref016]\], herpesvirus 6 \[[@pone.0220007.ref017]\], HTLV-1 \[[@pone.0220007.ref018]\], HIV \[[@pone.0220007.ref019],[@pone.0220007.ref020]\] and uropathogenic *E*. *coli* \[[@pone.0220007.ref021],[@pone.0220007.ref022]\] may use the cellular pathways of EV biogenesis for extracellular release. Recent studies in many laboratories have focused on exploring the utility of EVs isolated directly from biological fluids as disease biomarkers \[[@pone.0220007.ref023],[@pone.0220007.ref024]\]. Finally, EVs are also being developed as therapeutic agents capable of delivering drugs to specific tissues or organs in the body \[[@pone.0220007.ref003],[@pone.0220007.ref025],[@pone.0220007.ref026]\].

EVs are produced in at least two distinct ways. Fusion of endosomal multivesicular bodies (MVBs) with the plasma membrane releases intraluminal vesicles in the form of exosomes whereas direct outward budding of the plasma membrane generates ectosomes, also referred to as microvesicles. Based on the origin of EVs a number of proteins are well established as markers. Among these are the tetraspanins characterized by four membrane spanning helices, including most notably CD63 \[[@pone.0220007.ref027]--[@pone.0220007.ref031]\]. CD63 is predominantly localized to the intraluminal vesicles (ILVs) of late endosomes and MVBs and is thus enriched on exosomes \[[@pone.0220007.ref031]--[@pone.0220007.ref033]\]. Cytoplasmic proteins including members of the endosomal sorting complex required for transport (ESCRT) machinery, syntenin, and certain chaperones are also enriched in EVs \[[@pone.0220007.ref032],[@pone.0220007.ref034]\]. In addition, a variety of RNAs are present and thought to carry signals involved in cell-cell communication \[[@pone.0220007.ref035]--[@pone.0220007.ref037]\]. Several packaged miRNAs have been shown to exert specific biological effects supporting the notion that EV cargo is actively selected. Mechanistic understanding of how cargo is selected and packaged into EVs and how EV release is regulated will be important for future progress in this area.

EVs are small, ranging in size from \~50-140nm in diameter, making it difficult to monitor them using light-based methods \[[@pone.0220007.ref038]\]. Most studies of EVs depend on efficiently collecting them from cell culture media or biological fluids using high speed centrifugation or precipitation-based methods \[[@pone.0220007.ref039]\]. As cultured cells produce small quantities of EVs, analytical studies tend to require large volumes of conditioned media from cells cultured over one or more days which may be contaminated with material associated with cell injury and death. Moreover, typically used isolation procedures are inefficient, with extensive losses that preclude reproducible and quantitative yield \[[@pone.0220007.ref040]\]. Thus, better methods are needed to quantify EVs in small samples to facilitate chemical and genetic screens both to elucidate cell biological mechanisms involved in EV biogenesis and to identify strategies to modulate EV production.

Here, we have developed a new cell-based assay system to quantitate EV release with high sensitivity using stable cell lines expressing CD63 fused to a nanoluciferase reporter. Using this assay system, we screen a set of known biologically active compounds to reveal pathway(s) impacting EV release.

Materials and methods {#sec002}
=====================

Cells and Reagents {#sec003}
------------------

T-REx-293 cells were from Thermo Fisher (Cat\# R71007). U2-OS, U87-MG and SKMel28 were purchased from the American Type Culture Collection (Manassas, VA). Cells were transfected with the appropriate plasmids and stable transfectants were selected using 100 μg/ml Zeocin (Thermo Cat \#R25005) in DMEM (Gibco) with 10% fetal bovine serum (Atlanta Biologicals). Nano-Glo Luciferase Assay System was purchased from Promega (Cat \# N1110). Antibodies used in this study are listed in [S1 Table](#pone.0220007.s001){ref-type="supplementary-material"}.

Plasmid construction {#sec004}
--------------------

Plasmid pNL1.1\[*Nluc*\] carrying Nanoluciferase cDNA was a gift from Promega (Cat\# N1001). The Nluc gene was amplified using PCR with an upstream HA-tag along with appropriate cloning sites for expression as either a soluble cytoplasmic protein (HANL) or as fusion at the N-terminal end of CD63 gene (HANLCD63) in pcDNA4/TO plasmid (Thermo Fisher, Cat\# V102020) backbone.

Nanoluciferase assays {#sec005}
---------------------

TREx293 cells expressing HANL or HANLCD63 were grown in media without tetracycline and induced with 1μg/ml tetracycline overnight (17h). We also compared this with cells continuously maintained in media containing a low concentration of tetracycline (0.2μg/ml) and found no differences between the two paradigms. In this study, we maintained cells in media containing 0.2μg/ml Tet to maintain cells in a constitutively 'on' state. Typically, 50--100,000 cells per well were plated in a 24-well plate as needed for the conditions to be tested. After 18-24h for cell attachment, cells were washed twice with media to remove previously released EVs. Fresh media containing appropriate drugs (as indicated in the figures) was added to cells in 0.5ml media per well. Effects of the drugs were measured after indicated duration (typically 5 hours). At the end of the treatment, 250μl of conditioned media was removed into labeled 1.5ml tubes and centrifuged at 16000g for 5 minutes to remove large cell debris. Supernatants (media & EV) were collected into fresh tubes. To the cells in the remaining 250μl of media in the 24-well plate, 5μl of 10% Triton X100 was added (final 0.2%) to permeabilize cells and to release all contents (total). We confirmed that Triton X100 does not alter Nluc activity in HANL or HANLCD63 samples (see [S2 Fig](#pone.0220007.s003){ref-type="supplementary-material"}). 50μl of 'media & EV' samples and 1:10 diluted 'total' samples (5μl of sample+45ul of blank media) were transferred to 96-well plates (Costar \#3915). To each well containing sample, 25μl of Nano-Glo luciferase assay (Promega Cat\# N1110) reagent (prepared as per manufacturer's instructions) was added. Luminescence was measured immediately after reagent addition using a microplate reader (BioTek Synergy hybrid H2). Background luminescence in media-only blanks was also measured within each plate. Samples were measured in duplicates or triplicates and averages were plotted. To obtain an unbiased quantitation of EVs in various samples, a ratio of luminescence in 'media & EV' to that in 'total' cell lystates is reported, termed 'Fractional Release'.

Isolation of EVs by PEG precipitation {#sec006}
-------------------------------------

For precipitation of EVs from conditioned media, 1/3^rd^ volume of 40% PEG 3350 prepared in PBS was added to conditioned media for a final concentration of 10% PEG and incubated at 4C overnight. The mixture was centrifuged at 16,000g for 30 minutes at 4C. The pellet was resuspended in PBS.

Immunofluorescence {#sec007}
------------------

For immunofluorescence experiments, 50,000 cells were plated in 0.5ml on untreated \#1.5 coverslips (12mm circle) in separate wells of a 24-well plate. Cells were fixed in 4% paraformaldehyde in PBS for 20 minutes at room temperature and moved to fresh wells containing 1ml of PBS. Fixed cells were blocked and permeabilized in PBS containing 10% goat serum and 0.2% saponin for 1h. Blocked coverslips were incubated in primary antibody dilutions made in the blocking solution followed by 3 washes in PBS. Coverslips were incubated in secondary antibody dilutions made in the blocking solution followed by 3 washes in PBS. The coverslips were given a final rinse in PBS, mounted on clean glass slides with gelvatol and allowed to set overnight. Images were collected using a Nikon spinning disk confocal microscope equipped with a CCD camera and Nikon Elements software.

Immunoblotting {#sec008}
--------------

For immunoblotting experiments, cells were seeded at a density of 200,000 cells per well of a 6-well plate with 3ml of growth medium. The conditioned media was collected and subjected to PEG precipitation as described above. Cells were collected in 1ml of PBS into a 1.5ml tube and pelleted at 1000g for 3 minutes. The cell pellet was lysed in 100μl of hypotonic lysis buffer containing 50mM Tris.HCl (pH 7.5), 0.1% sodium dodecyl sulfate (SDS), 1X protease inhibitor cocktail (Roche) and 250 units/ml Benzonase (Sigma). After 5 minutes at room temperature, 35μl of 4X SDS-PAGE loading dye with 2-mercaptoethanol (for anti-HA blots) or without 2-mercaptoethanol (for anti-CD63 blots) was added and the samples were boiled for 5 minutes. Samples were separated by SDS-PAGE and blotted onto nitrocellulose membrane. Membrane was blocked with 10% non-fat dry milk in TBS with 0.1% Tween 20, followed by incubations in primary and secondary antibody dilutions with 3 washes after each step. Blots were developed using chemiluminescence and imaged on a BioRad Chemidoc. Bands were quantified using the BioRad ImageLab software.

Results {#sec009}
=======

Model development {#sec010}
-----------------

To develop a high sensitivity assay for detecting CD63-containing EVs released by limited numbers of cells over a short time into small volumes of culture media, we fused CD63 to the smallest available reporter luciferase known as Nanoluciferase (Nluc). In addition to fusing Nluc to CD63, we also developed a soluble Nluc reporter to monitor non-specific leakage of cellular contents resulting from cell injury or death. Nluc is a 19kDa luciferase based on a naturally occurring monomeric luciferase from the deep-sea shrimp, *Oplophorus sp*. \[[@pone.0220007.ref041]\]. Nluc utilizes the coelenterazine analog furimazine as substrate to produce a bright glow-type luminescence in an ATP-independent reaction. Nluc has been engineered for use in a variety of applications requiring quantitative and sensitive measurements \[[@pone.0220007.ref041]\]. To enable antibody-based monitoring of the fusion proteins we introduced a hemagglutinin (HA) tag at the N-terminus of Nluc to generate HANL ([Fig 1A](#pone.0220007.g001){ref-type="fig"}). Since CD63 has a GYXXΦ-motif near its C-terminus that binds clathrin adaptor proteins and is involved in sorting \[[@pone.0220007.ref042]\] and GFP fusions at the N-terminus have been successful in previous studies \[[@pone.0220007.ref043],[@pone.0220007.ref044]\], we fused HANL to the cytoplasmic N-terminus of CD63 to generate HANLCD63 ([Fig 1A](#pone.0220007.g001){ref-type="fig"}). HANL and HANLCD63 were cloned under a tetracycline (Tet)-inducible promoter and transfected into cells for selection of stable cell lines.

![Development of a model system to quantify CD63-containing EVs.\
(A) Schematic diagram showing the locations of HA-tag, Nanoluciferase and CD63. (B) Immunoblots of lysates of stably transfected TRex293 cells show inducible expression of HANLCD63 (top, anti-CD63 blot) and HANL (bottom, anti-HA blot). Samples from cells grown in the absence of Tet (-), in the presence of high Tet (+++, 1μg/ml for 17h), or when continuously cultured in low Tet (+, 0.2μg/ml over 3 passages). Lysates were blotted for actin to confirm equal loading. (C) Immunofluorescence of stably transfected TRex293 cells cultured in media containing low concentrations of Tet to express HANLCD63 or HANL were immunostained for LAMP1 and HA epitope tag. Bar = 10μm.](pone.0220007.g001){#pone.0220007.g001}

First, we examined the expression of these fusion proteins in Tet-inducible human embryonic kidney cells, TRex293 (HEK293), by immunoblotting ([Fig 1B](#pone.0220007.g001){ref-type="fig"}). Expression of HANL and HANLCD63 was induced by adding Tet to TRex293 cell lines. We compared expression in cells incubated overnight with a high concentration (1μg/ml) of Tet to that in cells grown in the continuous presence of a low concentration (0.2μg/ml) of Tet over three passages (about 10 generations). Tet-induced expression of HANL or HANLCD63 did not affect the rate of cell growth or cell number relative to uninduced controls (data not shown). Immunoblotting cell lysates for CD63 revealed that HANLCD63 was expressed inducibly at a level comparable to or less than that of endogenous CD63 ([Fig 1B](#pone.0220007.g001){ref-type="fig"}). Immunoblotting HANL samples for HA showed that HANL was strongly induced in response to Tet ([Fig 1B](#pone.0220007.g001){ref-type="fig"}). Quantitation of bands in [Fig 1B](#pone.0220007.g001){ref-type="fig"} showed that in Tet-induced samples expressing HANLCD63, an additional band at \~75kDa (band\#1 in [S1 Fig](#pone.0220007.s002){ref-type="supplementary-material"}) corresponding to HANLCD63 was observed. Relative quantitation of endogenous CD63 and HANLCD63 was not feasible since both endogenous CD63 and HANLCD63 migrated as multiple bands ([Fig 1B](#pone.0220007.g001){ref-type="fig"} and [S1 Fig](#pone.0220007.s002){ref-type="supplementary-material"}). Similar results were obtained using Tet-inducible U2OS cells ([S1 Fig](#pone.0220007.s002){ref-type="supplementary-material"}).

Next, we examined HANLCD63 and HANL localization by immunofluorescence and confocal microscopy ([Fig 1C](#pone.0220007.g001){ref-type="fig"}). We compared the distribution of HA-tag with that of the late endosome/lysosome protein, LAMP1. In cells expressing HANLCD63, HA-signal was distributed similarly to that of LAMP1 on intracellular organelles. A small proportion of HANLCD63 was also observed on the plasma membrane as expected for endogenous and overexpressed CD63 \[[@pone.0220007.ref044]\]. In contrast, HA staining in HANL expressing cells was diffusely present throughout the cytoplasm and distinct from LAMP1 confirming its cytoplasmic distribution as expected. HANLCD63 expressed in U2OS cells also mostly colocalized with LAMP1 ([S1 Fig](#pone.0220007.s002){ref-type="supplementary-material"}).

EV release {#sec011}
----------

To determine whether HANLCD63 will be useful as a marker of EV release, we next tested if released HANLCD63 is detectable in conditioned media in association with EVs. To do this, we added 10% polyethylene glycol (PEG) to conditioned cell media as described earlier \[[@pone.0220007.ref044]\] and measured Nluc activity in PEG soluble and insoluble fractions ([Fig 2A](#pone.0220007.g002){ref-type="fig"}). Although PEG precipitation is not selective for EVs, this method provides a simple and robust method for quantitative collection of EV-associated CD63 from conditioned media \[[@pone.0220007.ref044]\]. In HANL samples nearly all of the Nluc activity was found in the PEG soluble fraction. In HANLCD63 samples most of the Nluc activity was found in the PEG insoluble fraction consistent with the presence of HANLCD63 in EVs. We further confirmed this by immunoblotting PEG pellets with CD63 antibody ([Fig 2B](#pone.0220007.g002){ref-type="fig"}). In PEG pellets from HANL cell media only a single band of endogenous CD63 was detected with molecular weight of 50-60kDa (band\# 2), whereas in HANLCD63 derived samples additional bands at higher molecular weights (band\# 1) were observed consistent with additional recovery of HA tagged HANLCD63. The proportional signal in bands associated with HANLCD63 and endogenous CD63 is similar in cell lysates (shown in [Fig 1B](#pone.0220007.g001){ref-type="fig"}) and EVs (shown in [Fig 2B](#pone.0220007.g002){ref-type="fig"}), suggesting that the tagged and endogenous protein are incorporated similarly into EVs. Together with the localization of HANLCD63 to LAMP1-marked late endosomes and lysosomes, we conclude that the Nluc activity of HANLCD63 can be used to monitor EV associated CD63.

![Characterization of EV release using HANLCD63.\
(A) Precipitation of EVs using polyethylene glycol (PEG). Samples are--complete conditioned media (Total); supernatant after centrifugation at 14000g (14K sup); supernatant after PEG precipitation (PEG sup); pellet after PEG precipitation (PEG pel). (B) PEG pellets immunoblotted for CD63. Band intensities were quantified using the BioRad ImageLab software.](pone.0220007.g002){#pone.0220007.g002}

To quantitatively track EV release from HANLCD63 expressing cells, we measured Nluc activity in conditioned media as well as the total Nluc activity in HANLCD63 expressing cells. This allowed us to report EV release in comparative terms as the ratio of extracellular to total Nluc activity or 'fractional release'. To do this, we collected conditioned media at the time indicated and then replaced it with same volume of media containing 0.2% Triton X100 to extract HANLCD63 remaining in the cells. (See [S2 Fig](#pone.0220007.s003){ref-type="supplementary-material"} showing no effect of Triton X100 on Nluc activity of HANL and HANLCD63). In TRex293 (HEK293) cells, a small portion (0.1--0.3%) of total cellular HANLCD63 was released in EVs during a 5 hr collection period ([Fig 3](#pone.0220007.g003){ref-type="fig"}). For insight into how fractional release of EVs and cytoplasmic proteins varies among different cell lines, we generated and characterized U2OS, SKMel28 and U87-MG cells stably expressing HANLCD63. HANLCD63 was localized to LAMP1-positive endosomes as in TRex293 cells ([Fig 1C](#pone.0220007.g001){ref-type="fig"}, [S1 Fig](#pone.0220007.s002){ref-type="supplementary-material"} and data not shown). Interestingly, different cell lines exhibited different levels of EV release over a 5h period ([Fig 3](#pone.0220007.g003){ref-type="fig"}). While HEK293, U2OS and U87 cells showed a fractional release of between 0.1%-0.4%, SKMel28 cells released about 0.6% of total cellular HANLCD63. This result underscores the utility of this assay system for defining EV production by different types of cells. We used stably transfected TRex293 cells for most experiments in this study.

![EV release in different cell lines.\
Comparison of EV release from TRex293 (HEK293), U2OS, U87 and SKMel28 cells. Fractional release was compared using ordinary one-way ANOVA with Tukey's multiple comparisons test. \*\* = 0.005; \*\*\* = 0.0003; \*\*\*\* \<0.0001.](pone.0220007.g003){#pone.0220007.g003}

Important clues to understanding EV biogenesis and how it can be modulated can come from monitoring the kinetics of EV release. Given the inefficiencies of current exosome isolation methods, EV release has, however, mostly been studied after single prolonged collection times without time resolution or specific normalization to parent cells. Our model system is well suited to monitoring the kinetics of EV release. To measure fractional release of EV associated HANLCD63 or cytoplasmic HANL at different times after initiating collection, conditioned media and cell extracts were collected and used to measure Nluc activity. The time course of HANLCD63 release shows that low initial amounts of Nluc activity in the media (roughly 0.1% of cellular HANLCD63) steadily increase over 6h, reaching a fractional release of approximately 0.5%. This five-fold increase demonstrates both the sensitivity of this model system for detecting changes in EV release and, importantly, that under these baseline conditions EVs are being continuously released. In cells expressing HANL, the amount of Nluc present in the media (roughly 0.2--0.3% of cellular HANL) remains unchanged over 6 hours ([Fig 4A & 4B](#pone.0220007.g004){ref-type="fig"}). Based on the fact that most extracellular HANL was not precipitated by adding PEG ([Fig 2A](#pone.0220007.g002){ref-type="fig"}), we interpret its presence to reflect some form of cell or membrane damage, most likely associated with media change and washing at the beginning of the experiment.

![Kinetics of EV release.\
EV release over 6h as measured with HANLCD63 (A). (B) Extracellular release of cytoplasmic HANL protein over 6h.](pone.0220007.g004){#pone.0220007.g004}

Screen for pathway perturbants {#sec012}
------------------------------

Existing methods of bulk EV isolation and analysis create a bottleneck for efforts to advance understanding of EV biogenesis by screening compounds that modulate specific cellular machinery. To begin to assess involvement of different cellular machineries in release of CD63-containing EVs, we treated cells expressing HANL and HANLCD63 with various compounds for 5 hrs. Conditioned media was collected at the end of treatment and Nluc activity was measured ([Fig 5](#pone.0220007.g005){ref-type="fig"}). Note that this screening paradigm is most suitable for identifying compounds that stimulate EV release; longer EV collection times and/or cells that release high levels of EVs is likely to be needed to uncover inhibitors of EV biogenesis.

The following five groups of compounds were tested:

1.  [Ion balance perturbants:]{.ul} oubain to inhibit sodium-potassium ATPase; amiloride to block sodium channels; thapsigargin to inhibit the ER calcium channel, SERCA; MLSA1 to activate the endosomal calcium channel, TRPML1.

2.  [Lysosome perturbants]{.ul}: bafilomycin A1 to inhibit the V-ATPase proton pump; chloroquine as a lysosomotropic alkalizing agent.

3.  [Cytoskeleton perturbants:]{.ul} nocodazole to depolymerize microtubules; latrunculin A to block actin polymerization; jasplakinolide to induce actin polymerization.

4.  [Lipid perturbants]{.ul}: wortmannin to inhibit PI3 kinase; apilimod to inhibit PI3P-5-kinase; amiodarone to accumulate LBPA in endosomes \[[@pone.0220007.ref045]\], methyl β-cyclodextrin to reduce cellular cholesterol; U18666A to inhibit lysosomal cholesterol export; 1-aminodecylidene bis-phosphonic acid (ABPA) to inhibit acid sphingomyelinase; GW4869 to inhibit neutral sphingomyelinase.

5.  [Other perturbants:]{.ul} ML240 to inhibit VCP/p97 AAA ATPase; 17-DMAG to inhibit Hsp90; bortezomib to inhibit the proteasome; and Everolimus to inhibit mTORC1.

![Screen for pathway perturbants.\
HANLCD63 (A) and HANL (B) expressing TRex293 cells were treated with indicated compounds during a 5h EV collection. Nluc activity in media is shown as fold change over that released by control cells (Ctrl). Compounds were used at the following concentrations: (i) Control---Ctrl (No drugs); (ii) Ion balance perturbants---Oua (175nM Ouabain); Amil (100nM Amiloride); Thap (1μM Thapsigargin); MLSA1 (50μM MLSA1); (iii) Lysosome perturbants---Baf (200nM Bafilomycin); CQ (50μM Chloroquine); (iv) Cytoskeleton perturbants---Noco (1uμg/ml Nocodazole); LatA (2μM LatrunculinA); Jasp (2μM Jasplakinolide); (v) Lipid perturbants---Wort (10μM Wortmannin); Apil (2μM Apilimod); Amio (10μM Amiodarone); MBCD (1mM MβCyclodextrin); U18666A (7μM U18666A); ABPA (2μM 1-aminodecylidene bis-phosphonic acid); GW4869 (17.3μM GW4869); (vi) Other perturbants---ML240 (5μM ML240); 17DMAG (2μM 17-DMAG); Vel (100nM Velcade); Ever (10μM Everolimus). Data were compared in two ways--First, using two-way ANOVA with Tukey's multiple comparisons test to compare effects of each drug within each sample (HANL or HANLCD63). In HANLCD63 samples bafilomycin was significantly more effective in increasing EV release than control (p = 0.01) and CQ (p = 0.0002). Second, we also compared individual drug effects between HANL and HANLCD63 samples using multiple t-tests. This revealed that bafilomycin and latrunculin A significantly increases EV release in HANLCD63 (p values were 1.77e-8 for Baf and 6.37e-4 for LatA).](pone.0220007.g005){#pone.0220007.g005}

[Fig 5](#pone.0220007.g005){ref-type="fig"} shows the effect of these compounds on extracellular Nluc released from cells expressing HANL or HANLCD63. None of the compounds tested had a significant effect on extracellular Nluc activity in HANL samples ([Fig 5](#pone.0220007.g005){ref-type="fig"}), showing that as tested they did not compromise cell integrity. While most of the compounds tested also did not change extracellular Nluc released by cells expressing HANLCD63, a few significantly increased it indicating an enhancement of EV biogenesis and/or release.

Most notable was the large increase in release of CD63-containing EVs triggered by treating cells with bafilomycin, which we explore further below. Compounds that modulate Ca^2+^ homeostasis also increased HANLCD63 release. TRPML1/MCOLN, a Ca^2+^ channel on the endolysosomal membrane, has been implicated in control and release of endolysosomal Ca^2+^ and connected to exosome release \[[@pone.0220007.ref046]\]. Treating cells with MLSA1, an activator of TRPML1, doubled HANLCD63-marked EV release, consistent with these earlier reports. Treating cells with thapsigargin, which releases ER Ca^2+^ by inhibiting the sarco/endoplasmic reticulum Ca^2+^ ATPase (SERCA), also increased EV release, similar to previous observations \[[@pone.0220007.ref047]\]. These results suggest that increases in Ca^2+^ from multiple sources can enhance EV release.

We also observed that compounds affecting the actin cytoskeleton, but not microtubules, increased EV release. Both stabilizing actin filaments with jasplakinolide and inhibiting actin polymerization with latrunculin A increased EV release in our screen, potentially by relieving restrictions on exocytosis or enhancing blebbing of the plasma membrane. While we expected that transport of endosomes/MVBs along microtubules might be important for exocytosis and EV release, the lack of effect of nocodazole did not support such a role over the time course measured. Further studies will be required to determine the exact role of the cytoskeleton in EV biogenesis and/or release.

None of the lipid perturbants tested caused a significant change in CD63-EV release. Specifically, depleting cellular cholesterol with methyl-β-cyclodextrin or increasing it with U18666A had no effect on EV release. U18666A has previously been reported to have both stimulatory \[[@pone.0220007.ref048]\] as well as inhibitory roles in EV biogenesis \[[@pone.0220007.ref049]\]. Another lipid perturbant, apilimod, has been shown to cause a 50% increase in EV release over 20h of treatment \[[@pone.0220007.ref050]\]. Small stimulatory effects of this magnitude may not be obvious over the time course of our screen. Inhibitory effects of drugs such as GW4869 previously shown to act over 16h of treatment \[[@pone.0220007.ref051]\] were also not obvious in our screen. One possible explanation is that they would not be expected to inhibit exocytosis of existing MVBs. It is also possible that overexpressing HANLCD63 may diminish the sensitivity of EV biogenesis machinery to inhibitory drugs. Inhibitors of VCP/p97, Hsp90 or the proteasome also did not have significant effects at the concentrations tested. Finally, everolimus, a rapalog inhibitor of mTORC1 leading to hyperactivation of AKT signaling reproducibly enhanced EV release ([Fig 5](#pone.0220007.g005){ref-type="fig"}).

As above, we saw the most striking increase in EV release following treatment with bafilomycin, which inhibits the V-ATPase proton pump and thereby allows the lumenal pH of lysosomes to rise over seconds to minutes \[[@pone.0220007.ref052]\]. The observed increase in CD63-EV release is consistent with previous reports of bafilomycin enhancing various types of EV release \[[@pone.0220007.ref047],[@pone.0220007.ref053],[@pone.0220007.ref054]\], effects that have been attributed to the pH neutralizing effects of inhibiting the V-ATPase. Curiously, however, we found that treating cells with chloroquine, which rapidly neutralizes lumenal pH as a weak base, did not have any effect on HANLCD63 release. We set out to explore the basis for this striking dichotomy.

First, we asked whether bafilomycin enhances EV release from naïve, untransfected, HEK293 cells using traditional EV isolation and immunoblotting techniques. After treating HEK293 cells with vehicle or bafilomycin for 5 hrs, we examined the accumulation of marker proteins including CD63, CD9, flotillin and syntenin in PEG-concentrated EVs. Bafilomycin treatment robustly increased release of all of these EV-associated proteins, consistent with a broad based increase in EVs ([Fig 6A](#pone.0220007.g006){ref-type="fig"}). These results demonstrate that increased EV release following treatment with bafilomycin is a general phenomenon and not specific to cells overexpressing HANLCD63.

![Effects of lysosomal perturbants on EV release.\
(A) Analysis of EVs collected from naïve HEK293 cells treated with DMSO vehicle (-) or 200nM bafilomycin (+). PEG pellets from conditioned media collected over 5 hours were immunoblotted for CD63, CD9, flotillin 2 and syntenin as markers of EVs. (B) HEK293 cells were treated with vehicle (Ctrl), 200nM bafilomycin (Baf) or 50μM chloroquine (CQ). Cell lysates (Cells) or PEG pellets of conditioned media (EVs) were immunoblotted for CD63. (C) TRex293 cells expressing HANL or HANLCD63 were treated with indicated compounds to inhibit various aspects of lysosome function. Nluc activity was measured in conditioned media and expressed as fold change over vehicle treated (Ctrl) samples. Compounds used include--(i) V-ATPase inhibitors: Baf (200nM Bafilomycin); Con (100nM Concanamycin); (ii) weak bases: CQ (50μM Chloroquine); AmmCl (2mM Ammonium Chloride); (iii) protease inhibitors: Leu (2.5μM Leupeptin); Pep (15μM Pepstatin); E64d (20μM E64d); LPE mix (2.5μM Leupeptin, 15μM Pepstatin, 20μM E64d).](pone.0220007.g006){#pone.0220007.g006}

Next, to understand whether the difference in effects of the V-ATPase inhibitor and an alkalizing agent on EV release might be due to differing effects on the total amount of cellular CD63, we compared CD63 levels by immunoblotting cell lysates and PEG-concentrated EVs after treatment with bafilomycin or chloroquine ([Fig 6B](#pone.0220007.g006){ref-type="fig"} and [S3 Fig](#pone.0220007.s004){ref-type="supplementary-material"}). Cell-associated CD63 increased comparably after 5 hours in either bafilomycin or chloroquine, suggesting that both interfere with normal lysosomal activity. However, EVs isolated from these same cells showed that treatment with bafilomycin increased EV-associated CD63 far more dramatically than did treatment with chloroquine.

In order to test whether the enhanced release caused by bafilomycin is specific to EV secretion, we examined its effect on the secretion of proteins that pass through the classical secretory pathway and do not intersect EV biogenesis pathways. Specifically, we examined secreted nanoluciferase (SecNL), a model protein for classical secretion developed by fusing IL6 secretion signal to nanoluciferase ([S4 Fig](#pone.0220007.s005){ref-type="supplementary-material"}). Extracellular Nluc activity was measured in cells expressing HANLCD63 or SecNL during 2h after addition of bafilomycin. The extracellular:intracellular ratio (fractional release) for SecNL increased to \>600% within 2h under untreated conditions and was greatly inhibited by bafilomycin. Extracellular release of HANLCD63 was enhanced by bafilomycin as before. Bafilomycin has been previously observed to interfere with classical secretion \[[@pone.0220007.ref055],[@pone.0220007.ref056]\]. These results together with our results showing no effect of bafilomycin on release of cytoplasmic HANL demonstrate that the stimulatory effect of bafilomycin is specific for EV protein release and not attributable to non-specific release of cellular proteins resulting from dying cells.

Since MVBs either fuse with lysosomes for content degradation or with the plasma membrane to release ILVs as exosomes, we posited that blocking lysosomal function with other compounds would shed further light on trigger(s) responsible for enhanced EV release. Using HANLCD63 expressing TRex293 cells we first tested the effect of another inhibitor of V-ATPase function, concanamycin, as well as the weak base ammonium chloride \[[@pone.0220007.ref057],[@pone.0220007.ref058]\]. Concanamycin stimulated EV release to levels comparable to that seen with bafilomycin, while ammonium chloride again had no effect on EV release ([Fig 6C](#pone.0220007.g006){ref-type="fig"}). To test whether accumulation of un-degraded proteins within lysosomes might promote HANLCD63 release, we treated cells with lysosomal protease inhibitors (leupeptin, pepstatin, E64d) and measured extracellular Nluc. These inhibitors, either singly or in combination, also had no effect on HANLCD63 release suggesting that accumulation of undegraded proteins in endolysosomes is not a strong trigger for EV release ([Fig 6C](#pone.0220007.g006){ref-type="fig"}). To understand whether the stimulatory effect of V-ATPase inhibitors depends on changing organelle pH, we treated cells with bafilomycin together with ammonium chloride or chloroquine. Stimulated release of HANLCD63 by V-ATPase inhibition was unaffected by alkalizing agents ([S5 Fig](#pone.0220007.s006){ref-type="supplementary-material"}), suggesting that inhibiting V-ATPase alone was necessary and sufficient to promote enhanced release of HANLCD63.

Discussion {#sec013}
==========

We report development of a facile cell-based assay system for sensitively quantifying release of CD63-containing EVs in small volumes of conditioned culture media as a distinct phenomenon from non-specific cell lysis. To do this, we fused a small ATP-independent luciferase to the endolysosomal tetraspanin CD63 as a reporter for EVs. In addition, luciferase localized to the cytoplasm was used as a reporter for non-specific release cytoplasmic due to damage and injury to cells. This enables direct determination of EV marker release following different cell treatments. Using these markers, we established that different cultured cell lines differ in EV production. We also observed that EVs are constitutively and continuously released over a several hour time period, again distinct from cytosolic leakage. This system enabled a first pass broad-spectrum screen using compounds with known mechanistic targets, paving the way for future delineation of mechanisms of EV biogenesis. An important finding from this screen was the importance of V-ATPase activity in regulating EV release.

Our choice of luciferase was nanoluciferase (Nluc) because of its small size (19kDa), high stability and bright glow-type luminescence that is stable for \>30 min. Nluc luminescence is ATP-independent and \~150 times brighter than firefly or *Renilla* luciferase \[[@pone.0220007.ref059]\]. Further, Nluc has no disulfide binds and is therefore well suited for expression in the cytoplasm and on the cytoplasmic extensions of transmembrane proteins such as CD63; this is distinct from another small and bright luciferase derived from *Gaussia* which has many disulfide bonds and is therefore better suited for expression on lumenal extensions of transmembrane proteins \[[@pone.0220007.ref060]\]. Luciferase-based tracking of exosomes and other EVs has been previously explored. Danzer *et al*., used a split *Gaussia* luciferase system to investigate the packaging and release specifically of aggregated αSynuclein as cargo within exosomes in cultured cells \[[@pone.0220007.ref061]\]; the required aggregation step limited quantitative interpretation of EV release. Others have used membrane localized versions of *Gaussia* luciferase to monitor EVs *in vivo* \[[@pone.0220007.ref062],[@pone.0220007.ref063]\]. While this manuscript was under preparation, another report of Nluc fused to the C-terminal end of CD63 confirms the general utility of this tracer for tracking CD63-labelled membranes and EVs *in vitro* and *in vivo* \[[@pone.0220007.ref064]\]. However, C-terminal fusion of tracers to CD63 may perturb function of the GYXXΦ sorting signal present at the C-terminus of CD63 \[[@pone.0220007.ref042],[@pone.0220007.ref065],[@pone.0220007.ref066]\].

As proof-of concept for using this system in pharmacological screens, we tested the effect of treating Nluc marker expressing cells with compounds known to perturb ionic homeostasis, lysosomal function, cytoskeletal structure and dynamics, lipid metabolism and proteostasis. Our screening paradigm with a short EV collection time was better suited to identifying compounds that enhance EV release. Results from this screen demonstrate that inhibitors of the V-ATPase, bafilomycin and concanamycin, were profound stimulators of EV release demonstrating the utility of this facile assay system in drug and genetic screens. However, with short EV collection times we were unable to validate the effects of the previously described inhibitor of EV biogenesis GW4869. This was potentially because the incubation period of 5h is shorter than that (16h) reported in literature \[[@pone.0220007.ref051]\] and needed to observe an effect or because overexpression of HANLCD63 may enhance EV biogenesis and obscure the effect of inhibitory drugs. Increases in the duration of drug treatment and EV collection may make the assay more suitable for screening for inhibitors of EV biogenesis.

Our findings of bafilomycin-stimulated EV release are in agreement with earlier observations showing increased secretion of lysosomal enzymes upon treatment with bafilomycin \[[@pone.0220007.ref053]\]. Bafilomycin-mediated stimulation of EV release was also observed in a recent paper \[[@pone.0220007.ref054]\], wherein it was also shown that in HeLa cells, exosomes are retained on the plasma membrane by the action of tetherin. These authors also demonstrated that treatment of cells with bafilomycin interrupts cholesterol trafficking leading to cholesterol accumulation in endosomes and exosomes. In our study, we found that compounds that increase or decrease cholesterol did not alter EV release suggesting that accumulation of endosomal cholesterol was not likely to be the trigger for increased EV release. In K562 cells, small increases were observed in exosome release after treatment with either bafilomycin or chloroquine \[[@pone.0220007.ref047]\]. Importantly, in our HEK293-based system, unlike bafilomycin treatment, EV release could not be increased either by alkalizing of endosomal lumen or by inhibiting lysosomal proteases. This suggests that neither the lumenal pH of endosomes nor the lysosomal degradative capacity was responsible for increased exocytosis. An *in vivo* study in *C*. *elegans* revealed that the V-ATPase mediated apical secretion of exosomes containing hedgehog-related proteins \[[@pone.0220007.ref067]\].

How might V-ATPase inhibition by bafilomycin or concanamycin stimulate EV release? EV biogenesis can be influenced by perturbations at various steps including generation of intralumenal vesicles, endosomal trafficking of CD63, motility of endosomes as well as exocytosis. It is possible that the V-ATPase complex itself might somehow be responsible for increased exocytosis. Bafilomycin and concanamycin bind to V~0~-ATPase complex presumably at the interface of the a- and c-subunits that sits in the lipid bilayer \[[@pone.0220007.ref068]--[@pone.0220007.ref073]\]. Binding of these inhibitors is thought to interfere with the helical swiveling required for proton translocation \[[@pone.0220007.ref074]\]. It is thought that association and dissociation of V~1~-ATPase complex with the V~0~ complex is a key regulatory step for many cellular pathways \[[@pone.0220007.ref074]\] including exocytosis of synaptic vesicles \[[@pone.0220007.ref075]\]. The V~0~-V~1~ ATPase complex has been shown to recruit key signaling machinery such as the mTOR kinase that sense endolysosomal function and generate an appropriate response to regulate protein synthesis and cholesterol transport (reviewed in \[[@pone.0220007.ref076],[@pone.0220007.ref077]\]). Kozik et al, found an important role for V-ATPase in clathrin-coated vesicle formation \[[@pone.0220007.ref078]\]. Johnson et al, found that lower V-ATPase activity coincided with localization of endolysosomes to the cell periphery \[[@pone.0220007.ref052]\], which could increase the probability of exocytosis and EV release. Merkulova et al, mapped several protein-protein interactions with the B1 subunit of the cytoplasmic V~1~ ATPase complex and found that some (eg, rabconnectin 3) were involved in Rab3-mediated exocytosis \[[@pone.0220007.ref079]\]. V-ATPase was found to be required for Rab27B-dependent invasive growth and metastasis in breast cancer \[[@pone.0220007.ref080]\] suggesting that V-ATPase and the Rab GTPase implicated in exosome biogenesis were functionally connected. Clear understanding of whether bafilomycin increases or decreases the abundance of the V~0~-V~1~ holoenzyme and its role in the association of exocytic machinery will illuminate its mode of action in exocytosis.

Because MVBs can target lumenal cargo proteins for either degradation by fusion with lysosomes or extracellular release by fusion with plasma membrane, it is reasonable to hypothesize that the V-ATPase may contribute to general proteostasis by its ability to sense endosomal/lysosomal function in order to shunt undegraded potentially damaging proteins out of the cell by exocytosis. In support of this idea, it has been observed that in *C*. *elegans* neurons stress resulted in the expulsion of a bolus of protein aggregates by exocytosis \[[@pone.0220007.ref081]\]. The autophagy protein, Atg5, was shown to dissociate the V1E subunit from the V~0~-V~1~ ATPase complex to promote exosome production \[[@pone.0220007.ref082]\]. These observations suggest that reduced V-ATPase function due to accumulation of protein aggregates in endosomes/lysosomes may lead to extracellular release of potentially pathogenic protein aggregates which in turn could spread disease pathology in the brain. Further work is needed to delineate the underlying mechanisms by which V-ATPase facilitates EV release.

Conclusions {#sec014}
===========

In this study, we have developed a novel model system for quantitatively assaying small amounts of CD63-containing EVs. We have demonstrated the utility of such a model system in screening for compounds affecting pathways important in cargo-selection, packaging and exocytosis events leading to EV release. Using this novel model system, we have identified the V-ATPase as an important regulator of EV secretion. Given the bright luminescence from Nluc, we predict that the construct presented in this paper may also be successfully used *in vivo* in surface as well as deep tissues as previously demonstrated \[[@pone.0220007.ref083]\].
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###### List of antibodies used in this study.

(DOCX)

###### 

Click here for additional data file.

###### Expression and endosomal localization of HANLCD63 in U2OS cells.

\(A\) Quantitation of the CD63 blot in [Fig 1B](#pone.0220007.g001){ref-type="fig"}. Six independent bands were identified in Tet-induced samples (red bars, +++ and green bars, +) whereas five bands were identified in uninduced samples (blue bars, -). An image of the gel with the respective bads is shown as an inset. (B) U2OS (tet-inducible) cells stably transfected with HANLCD63 immunoblotted for CD63 with or without induction of exppression with tetracyclin. (C) Immunofluorescence of stably transfected cells with HA tag (green) and Lamp1 (red) shows endosomal localization of HANLCD63 in Lamp1-positive late endosomes.
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Click here for additional data file.

###### Triton X-100 does not affect nanoluciferase activity in EVs.

EVs were isolated from HANL and HANLCD63 expressing TRex293 cells by ultracentrifugation at 100000g for 90 minutes at 4C. The EV pellets were resuspended in PBS containing no detergent (-Tx100) or with 0.1%Triton X-100 (+Tx100) and the NLuc luminescence was measured. No difference was obvious between -Tx100 and +Tx100 samples demonstrating that addition of Tx100 to NLuc samples does not affect luminescence.
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Click here for additional data file.

###### Quantitation of the blots in [Fig 6B](#pone.0220007.g006){ref-type="fig"}.

Band intensities within equal sized boxes in each lane of the blots for cell lysates and EVs was normalized to the intensity in the respective control (Ctrl) sample.
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###### 

Click here for additional data file.

###### Bafilomycin does not stimulate release of proteins secreted through classical secretion pathway.

Extracellular Nluc activity was measured in HANLCD63 and SecNL for 2h under control (Ctrl; blue lines) or after addition of bafilomycin (Baf; red lines). While extracellular release of HANLCD63 was enhanced by bafilomycin, secretion of SecNL was greatly inhibited.
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Click here for additional data file.

###### Ammonium chloride does not affect bafilomycin-stimulated EV secretion.

NLuc luminescence was measured in conditioned culture media of HANL and HANLCD63 cells treated without (-Baf) or with 200nM bafilomycin (+Baf) and were either not co-treated (-AmmCl) or co-treated with 10mM ammonium chloride (+AmmCl) as an alkalizing agent. No difference was observed in +Baf samples with or without ammonium chloride cotreatment. This result shows that alkalizing agents do not influence increased EV release due to V-ATPase inhibitors.
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Click here for additional data file.
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